Novavax Shares Fall 83% on Failed Drug Trial

September 16, 2016

Novavax got a bad news today as its vaccine for respiratory disease failed badly in late stage trial. The news wiped out 83 percent of its shares and a huge chunk of its $2.2 billion market cap. To see what the crowd is discuss regarding this news, you’re already in the right place, right here on Sentifi.

Sentifi top attentions September 16

2/ Novavax Inc: Tries to cope with the financial loss

Top themes and market attention on:

“We are both surprised and disappointed by the outcome of the Resolve trial,” Novavax Reseach Chief Gregogy Glenn said. The company’s drug met neither the main nor the secondary efficacy goals of a Phase III trial.

3/ Bayer: 67 percent of farmers do not approve of Bayer-Monsanto merger

Bayer got no love from farmers, but the attention is enough for it to appear in Sentifi top attentions.

2,632 people took part in a Farm Journal Media poll to voice their opinion about the Bayer-Monsanto merger. 67 percent are against the merger, and only 10 percent voted in favor of it. Bayer said in a statement that it will keep delivering the benefits to the farmers, and they won’t be affected negatively.

4/ Morrisons: Shares rise 7.5 percent thanks to quarterly sales growth

With sales at stores open for more than a year rising 2 percent in the latest quarter, the U.K.’s fourth largest grocer was able to secure the third consecutive quarter of sales growth. That said, it remains cautious about the Brexit effect on the economy, and warned of some uncertainties.

5/ Reynolds American Inc: Appoints John Boehner as a board member

Former Speaker of the House of Representatives John Boehner has officially join the board of the second largest tobacco company in the U.S. The company is currently struggling to compete with innovative tobacco products in the likes of e-cigarettes and vaping.

6/ Reliance Communications: Shares rise 3.62 percent on merger plan

The Indian Internet access and telecommunications company plans to merge its mobile business with Indian network operator Aircel to cut debt. Reliance and Aircel’s parent company will each own half of the merged carrier.

7/ Aerie Pharma: Announces a secondary shares offering after big stock jump

After its shares increased 45 percent thanks to the good performance of its eye treatment in clinical studies, the company announced it will have a secondary offering of $50 million in shares. The purpose is to help finance commercialization of its other eye treatment.

8/ Hinduja Foundries: Approves merger with Ashok Leyland

Sentifi jumps to Sentifi Top Attentions thanks to its potential merger with Ashok.
Sentifi Hinduja and Ashok Leyland will soon merge.

India’s largest casting maker Hinduja has greenlighted the merger with commercial vehicle maker Ashok. Market experts believe the merger will be a loss to Ashok, which is evident in its shares dropping 3.43 percent following the news. Hinduja is making a loss with its business, with its performance going downhill in the last five years.

9/ SNB: Keeps rates unchanged

The bank decided to keep its deposit rate at minus 0.75 percent and its three-month Libor band target unchanged at minus 0.25 percent to minus 1.25 percent. The intent of the bank is to make “Swiss franc investments less attractive, thereby easing upward pressure on the currency.”

10/ BRICS Econ: Increasing consumer awareness fuels growth of oral care market

Organized retailing, rising per capita income, increasing consumer spending on personal care products and consumer preferences for value-added products contribute to the growth of the oral care market. The market is expected to grow 20 percent by 2020.

If you want to harness the wisdom and insights from the crowd to monitor your portfolio free of charge, sign up at Sentifi.